Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting

Table 1 Patient demographics n (%)

	IBD1	CD	UC
Total	258	154	93
Male	127 (49.2)	78 (50.6)	48 (51.6)
Mean age, yr	40.88 ± 16.67	39.59 ± 16.28	43.66 ± 17.04
IFX Pre-SONIC	111 (43.0)	73 (47.4)	30 (32.2)
6-MP/AZA use	56 (21.7)	35 (22.7)	18 (19.4)
MTX use	4 (1.6)	3 (1.9)	1 (1.1)

¹The “IBD Total” group includes the “CD Total” and “UC Total” groups, as well as 11 patients with indeterminate colitis. IBD: Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis; IFX: Infliximab; 6-MP: 6-mercaptupurine; AZA: Azathioprine; MTX: Methotrexate.